Check out Jonathan D. Grinstein, PhD's take on growing momentum for cell and gene therapy based on his reporting from ARM’s recent Meeting on the Mesa for Inside Precision Medicine. https://t.co/NZtJTO4SOA #CGMesa25 #cellandgenetherapy

And that’s a wrap for ARM's 2025 Cell and Gene Meeting on the Mesa. And what a week it was! Thanks to our sponsors, speakers, and partners for making this year’s Meeting on the Mesa possible, and to our amazing patient advocates for sharing their inspirational stories. #CGMesa25

2/2 During his opening remarks at this year’s Cell & Gene Meeting on the Mesa, ARM CEO Tim Hunt highlighted how these trends show promising momentum for sustainable growth in the sector. View the full #ReasonstoBelieve analysis and deck here: https://t.co/Aw2QbDA5hQ #CGMesa25

2025 has also been a year of notable capital raises for cell and gene therapy companies, along with several announcements around large partnerships and acquisitions with big biopharma. 1/2

Day 2 of #CGMesa25 has come to a close. Thank you to all our speakers, attendees, and partners for contributing to such an engaging and productive day. The energy and collaboration here in Phoenix continue to drive this community forward. See you tomorrow for the final day!

What other #ReasonstoBelieve in cell and gene therapy did ARM CEO Tim Hunt discuss during his opening remarks at #CGMesa25? There are a number of pipeline trends and potential breakthroughs that could catapult the sector to new heights.

3/3 Additionally, analyst consensus forecasts show the cell and gene therapy market is expected to grow exponentially over the next 5 years.

2/3 A basket of public CGT equities spanning different modalities and clinical stages is outperforming the S&P Biotech Index Fund after significantly underperforming it in the last two years.

During today’s opening remarks at #CGMesa25, ARM CEO Tim Hunt highlighted why 2025 is a year of reasons to believe in the cell and gene therapy sector. #ReasonstoBelieve 1/3

ARM has kicked off this year’s Meeting on the Mesa with a big announcement! At the conference's opening, we officially elected our 2026 Board of Directors. Congratulations to these distinguished individuals who will be key to ARM’s sector leadership. ➡️ https://t.co/H9aWtWBMKl

Today in Phoenix, ahead of #CGMesa25, ARM hosted an Investor and CEO Summit. The event brought together cell and gene therapy executives, investors, and analysts to exchange insights on navigating today’s capital markets.

Exciting news! ARM has updated our look and image to better represent the innovative and transformative impact of the cell and gene therapy sector. We have also launched a brand new website that provides a refreshed look at ARM's mission. See it here. ➡️ https://t.co/LWoq11KSLA

🚨 Just 10 days to go until North America’s leading gathering for the cell and gene therapy sector! The 2025 Cell & Gene Meeting on the Mesa brings together the field for three dynamic days On the fence? There is still time to register: https://t.co/uu9Oq5wPoQ #CGMesa25

3/3 A regulatory submission is expected in 2026. If approved, it would be the first genetic treatment ever approved for the disease. There are currently no approved therapies to delay the onset or to slow the disease’s progression.

2/3 Trial data demonstrated that the therapy slowed the progression of Huntington's disease by 75% after three years. The therapy uses an AAV vector to deliver miRNA to brain cells and lower the production of harmful proteins.

A significant breakthrough was achieved today in gene therapy! ARM member @uniQure_NV announced the topline results of a pivotal trial for its AAV gene therapy to treat Huntington's disease, a rare and devastating genetic disorder. https://t.co/42VrdPJBZP 1/3

@BloodCancerUtd We urge Congress to pass this commonsense policy solution to ensure children get access to the care they deserve.

Due of the specialized nature of CGTs, there are a limited number of qualified treatment centers where patients can receive them. Our friends at @BloodCancerUtd show how the Accelerating Kids’ Access to Care Act would reduce care delays for Medicaid patients.

Tomorrow the House Energy and Commerce Committee is marking-up the Give Kids a Chance Act, a bipartisan bill that reauthorizes the FDA's Rare Pediatric Disease Priority Review Voucher Program. Read ARM's letter on the legislation here:

3/3 Both therapies became blockbuster products just a few years after FDA approval. What do they & other successful CGT products have in common? ➡️ Global sales footprint ➡️ Address a high unmet need with high clinical efficacy ➡️ Established early access capabilities